{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:46:19Z","timestamp":1794257179989,"version":"4.9.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Risankizumab, a selective IL-23 inhibitor, has emerged as a promising therapeutic agent for moderate-to-severe plaque psoriasis. This study aims to systematically assess its efficacy and safety through an updated meta-analysis of randomized controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A comprehensive literature search of PubMed\/MEDLINE, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov was conducted from their inception to 15 April 2025 for RCTs comparing risankizumab with placebo or active comparators in adults with moderate-to-severe psoriasis. Data were pooled using random-effects models (RevMan 5.4), and heterogeneity was assessed using\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      statistics. The Cochrane Risk of Bias Tool 2 (RoB 2) was utilized for risk of bias assessment of each included RCT. The forest plots were generated using risk ratios (RRs) with 95% confidence intervals (CIs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eleven RCTs (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =\u00a02664 patients) were included in the study. Risankizumab showed significantly greater efficacy than placebo for PASI 75 (OR: 23.93, 95% CI: 7.80\u201373.41), PASI 90 (OR: 18.11, 95% CI: 5.03\u201365.24), and PASI 100 (OR: 30.31, 95% CI: 12.36\u201374.34). Compared to active comparators (ustekinumab and adalimumab), risankizumab demonstrated a superior PASI 90 response (OR 3.40, 95% CI: 2.32\u20134.96). Quality of life (DLQI) improved significantly (OR: 31.53, 95% CI: 19.46\u201351.09). No increased risk of SAEs was observed (OR: 0.71, 95% CI: 0.33\u20131.54), although the infection risk was slightly elevated (OR: 1.38, 95% CI: 0.87\u20132.18).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This meta-analysis confirms the superiority of risankizumab over placebo and other biologics in achieving complete or near-complete skin clearance, with a favorable safety profile. These findings suggest that risankizumab is a first-line biologic agent for moderate-to-severe plaque psoriasis, although infection monitoring remains warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005155","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:00:11Z","timestamp":1778846411000},"page":"3541-3555","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of risankizumab in moderate to severe psoriasis: an updated systematic review and meta-analysis"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1533-7319","authenticated-orcid":false,"given":"Hafsa","family":"Shuja","sequence":"first","affiliation":[{"name":"Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6211-7522","authenticated-orcid":false,"given":"Kanza","family":"Farhan","sequence":"additional","affiliation":[{"name":"Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6638-7598","authenticated-orcid":false,"given":"Umer","family":"Wamiq","sequence":"additional","affiliation":[{"name":"Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4228-6476","authenticated-orcid":false,"given":"Muhammad Saad","family":"Khan","sequence":"additional","affiliation":[{"name":"Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6908-0836","authenticated-orcid":false,"given":"Muhammad Burhan","family":"Tariq","sequence":"additional","affiliation":[{"name":"Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9994-3414","authenticated-orcid":false,"given":"Shanza","family":"Shakir","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Sindh, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6275-343X","authenticated-orcid":false,"given":"Muhammad","family":"Uzair","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Sindh, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-560X","authenticated-orcid":false,"given":"Izere","family":"Salomon","sequence":"additional","affiliation":[{"name":"Department of General Medicine and Surgery, University of Rwanda, College of Medicine and Health Sciences, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"R1-20260810","article-title":"Psoriasis: comprehensive review of pathogenesis, clinical manifestations, and advancements in treatment strategies","author":"Pingale","year":"2024","journal-title":"Int J Pharm Sci"},{"key":"R2-20260810","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/jcm14041312","article-title":"Therapeutic advancements in psoriasis and psoriatic arthritis","volume":"14","author":"Yi","year":"2025","journal-title":"J Clin Med"},{"key":"R3-20260810","doi-asserted-by":"crossref","first-page":"1616\u201326","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R4-20260810","doi-asserted-by":"crossref","first-page":"e13706","DOI":"10.1111\/cts.13706","article-title":"Risankizumab: mechanism of action, clinical and translational science","volume":"17","author":"Pang","year":"2024","journal-title":"Clin Transl Sci"},{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"3879\u201383","DOI":"10.2147\/DDDT.S167149","article-title":"Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis","volume":"12","author":"Haugh","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R6-20260810","first-page":"1235\u201345","article-title":"Risankizumab: a review in moderate to severe plaque psoriasis","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"R7-20260810","doi-asserted-by":"crossref","first-page":"e14487","DOI":"10.1111\/dth.14487","article-title":"Efficacy and safety of risankizumab in moderate to severe psoriasis: a systematic review and meta-analysis","volume":"34","author":"Singh","year":"2021","journal-title":"Dermatol Ther"},{"key":"R8-20260810","article-title":"Transparency in the reporting of artificial intelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci Review"},{"key":"R9-20260810","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"bmj"},{"key":"R10-20260810","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan \u2013 a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"R16-20260810","doi-asserted-by":"crossref","first-page":"2063\u201375","DOI":"10.1007\/s13555-022-00776-0","article-title":"Risankizumab for the treatment of moderate to severe plaque psoriasis in the Russian Federation","volume":"12","author":"Odnopozova","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R17-20260810","doi-asserted-by":"crossref","first-page":"50\u201359","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy\u2013assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"British J Dermatol"},{"key":"R18-20260810","doi-asserted-by":"crossref","first-page":"649\u201358","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R19-20260810","doi-asserted-by":"crossref","first-page":"650\u201361","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"R20-20260810","doi-asserted-by":"crossref","first-page":"686\u201394","DOI":"10.1111\/1346-8138.14941","article-title":"Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the Susta IMM phase 2\/3 trial","volume":"46","author":"Ohtsuki","year":"2019","journal-title":"J Dermatol"},{"key":"R21-20260810","doi-asserted-by":"crossref","first-page":"576\u201386","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"R22-20260810","doi-asserted-by":"crossref","first-page":"116\u201324","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti\u2013IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R23-20260810","doi-asserted-by":"crossref","first-page":"1150\u201357","DOI":"10.1016\/j.jaad.2024.07.1521","article-title":"A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement","volume":"91","author":"Lebwohl","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"R24-20260810","doi-asserted-by":"crossref","first-page":"593\u2013602","DOI":"10.1111\/1346-8138.17659","article-title":"Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: results from the randomized, phase 3 JumPPP study","volume":"52","author":"Okubo","year":"2025","journal-title":"J Dermatol"},{"key":"R25-20260810","doi-asserted-by":"crossref","first-page":"1551\u201360","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"R26-20260810","first-page":"1493\u2013503","article-title":"Selective interleukin-23 p19 inhibition: another game changer in psoriasis?","volume":"77","author":"Torres","year":"2017","journal-title":"Focus on Risankizumab Drugs"},{"key":"R27-20260810","doi-asserted-by":"crossref","first-page":"1331217","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Front Immunol"},{"key":"R28-20260810","doi-asserted-by":"crossref","first-page":"1099\u2013109","DOI":"10.1007\/s13555-020-00428-1","article-title":"Association between patient-and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in real life (PSO-BIO-REAL)","volume":"10","author":"Lacour","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R29-20260810","first-page":"1\u20134","article-title":"Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis: interim analysis from the VALUE global prospective post-marketing observational study at 25 months","author":"Tha\u00e7i","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R30-20260810","doi-asserted-by":"crossref","first-page":"235\u201339","DOI":"10.3109\/09546634.2014.943687","article-title":"Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis","volume":"26","author":"Viswanathan","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"R31-20260810","doi-asserted-by":"crossref","first-page":"260\u201370","DOI":"10.1159\/000113150","article-title":"Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis","volume":"216","author":"Revicki","year":"2008","journal-title":"Dermatology"},{"key":"R32-20260810","doi-asserted-by":"crossref","first-page":"19\u201326","DOI":"10.1080\/09546634.2018.1473551","article-title":"Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3","volume":"30","author":"Kem\u00e9ny","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"R33-20260810","doi-asserted-by":"crossref","first-page":"702776","DOI":"10.3389\/fmed.2021.702776","article-title":"A review of the efficacy and safety of biologic agents targeting IL-23 in treating psoriasis, with a focus on tildrakizumab","volume":"8","author":"Ghazawi","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R34-20260810","doi-asserted-by":"crossref","first-page":"569\u201378","DOI":"10.1080\/09546634.2017.1422591","article-title":"A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis","volume":"29","author":"Bilal","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"R36-20260810","doi-asserted-by":"crossref","first-page":"523\u201324","DOI":"10.1080\/09546634.2019.1643588","article-title":"Assessing efficacy and the speed of response in psoriasis treatment","volume":"30","author":"Light","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"R37-20260810","doi-asserted-by":"crossref","first-page":"831\u201339","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"R38-20260810","doi-asserted-by":"crossref","first-page":"1149\u201358","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up","volume":"89","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R41-20260810","doi-asserted-by":"crossref","first-page":"629\u201337","DOI":"10.1093\/rheumatology\/keac342","article-title":"Risankizumab improved health-related quality of life, fatigue, pain, and work productivity in psoriatic arthritis: results of keepsake 1","volume":"62","author":"Kristensen","year":"2023","journal-title":"Rheumatology"},{"key":"R42-20260810","doi-asserted-by":"crossref","first-page":"221\u201329","DOI":"10.2147\/CCID.S296544","article-title":"Risankizumab for the treatment of moderate to severe psoriasis: impact on health-related quality of life and psychological wellbeing","volume":"16","author":"Gracia-Caza\u00f1a","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R43-20260810","doi-asserted-by":"crossref","first-page":"20406223231206225","DOI":"10.1177\/20406223231206225","article-title":"Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Chiu","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"key":"R44-20260810","doi-asserted-by":"crossref","first-page":"313\u201321","DOI":"10.1016\/j.jid.2016.08.034","article-title":"Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry","volume":"137","author":"D\u00e1vila-Seijo","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R45-20260810","doi-asserted-by":"crossref","first-page":"385\u2013400","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R46-20260810","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"IL-23-IL-17 immune axis: discovery, mechanistic understanding, and clinical testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"R47-20260810","doi-asserted-by":"crossref","first-page":"ii20","DOI":"10.1093\/ecco-jcc\/jjac023","article-title":"What can IBD specialists learn from IL-23 trials in dermatology?","volume":"16","author":"Valenti","year":"2022","journal-title":"J Crohn\u2019s Colitis"},{"key":"R48-20260810","doi-asserted-by":"crossref","first-page":"1345\u201355","DOI":"10.1007\/s13555-021-00556-2","article-title":"Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from the Czech Republic","volume":"11","author":"Gkalpakiotis","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R49-20260810","doi-asserted-by":"crossref","first-page":"839\u201350","DOI":"10.1002\/cpt.2831","article-title":"Population pharmacokinetic and exposure\u2013response analyses for efficacy and safety of risankizumab in patients with active crohn\u2019s disease","volume":"113","author":"Suleiman","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"R50-20260810","doi-asserted-by":"crossref","first-page":"2805\u201322","DOI":"10.1097\/JS9.0000000000004413","article-title":"Current concerns and future directions of large language model ChatGPT in medicine: a machine-learning-driven global-scale bibliometric analysis","volume":"112","author":"Guo","year":"2026","journal-title":"Int J Surg"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:00:33Z","timestamp":1786359633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005155","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2025-12-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}